Daskalopoulou Aphrodite, Giotaki Sotiria G, Toli Konstantina, Minia Angeliki, Pliaka Vaia, Alexopoulos Leonidas G, Deftereos Gerasimos, Iliodromitis Konstantinos, Dimitroulis Dimitrios, Siasos Gerasimos, Verikokos Christos, Iliopoulos Dimitrios
Laboratory for Experimental Surgery and Surgical Research "N.S. Christeas", Athens Medical School, National and Kapodistrian University of Athens, 115 27 Athens, Greece.
Second Department of Cardiology, National and Kapodistrian University of Athens, 115 27 Athens, Greece.
Biomedicines. 2023 Apr 25;11(5):1273. doi: 10.3390/biomedicines11051273.
There is a need for clinical markers to aid in the detection of individuals at risk of harboring an ascending thoracic aneurysm (ATAA) or developing one in the future.
To our knowledge, ATAA remains without a specific biomarker. This study aims to identify potential biomarkers for ATAA using targeted proteomic analysis.
In this study, 52 patients were divided into three groups depending on their ascending aorta diameter: 4.0-4.5 cm ( = 23), 4.6-5.0 cm ( = 20), and >5.0 cm ( = 9). A total of 30 controls were in-house populations ethnically matched to cases without known or visible ATAA-related symptoms and with no ATAA familial history. Before the debut of our study, all patients provided medical history and underwent physical examination. Diagnosis was confirmed by echocardiography and angio-computed tomography (CT) scans. Targeted-proteomic analysis was conducted to identify possible biomarkers for the diagnosis of ATAA.
A Kruskal-Wallis test revealed that C-C motif chemokine ligand 5 (CCL5), defensin beta 1 (HBD1), intracellular adhesion molecule-1 (ICAM1), interleukin-8 (IL8), tumor necrosis factor alpha (TNFα) and transforming growth factor-beta 1 (TGFB1) expressions are significantly increased in ATAA patients in comparison to control subjects with physiological aorta diameter ( < 0.0001). The receiver-operating characteristic analysis showed that the area under the curve values for CCL5 (0.84), HBD1 (0.83) and ICAM1 (0.83) were superior to that of the other analyzed proteins.
CCL5, HBD1 and ICAM1 are very promising biomarkers with satisfying sensitivity and specificity that could be helpful in stratifying risk for the development of ATAA. These biomarkers may assist in the diagnosis and follow-up of patients at risk of developing ATAA. This retrospective study is very encouraging; however, further in-depth studies may be worthwhile to investigate the role of these biomarkers in the pathogenesis of ATAA.
需要临床标志物来帮助检测有胸段升主动脉瘤（ATAA）或未来发生胸段升主动脉瘤风险的个体。
据我们所知，ATAA仍没有特异性生物标志物。本研究旨在通过靶向蛋白质组分析确定ATAA的潜在生物标志物。
在本研究中，52例患者根据升主动脉直径分为三组：4.0 - 4.5厘米（n = 23）、4.6 - 5.0厘米（n = 20）和>5.0厘米（n = 9）。共有30名对照者为内部人群，种族与病例匹配，无已知或可见的与ATAA相关症状，且无ATAA家族史。在我们的研究开始之前，所有患者均提供了病史并接受了体格检查。通过超声心动图和血管计算机断层扫描（CT）扫描确诊。进行靶向蛋白质组分析以确定用于诊断ATAA的可能生物标志物。
Kruskal-Wallis检验显示，与生理主动脉直径的对照受试者相比，C-C基序趋化因子配体5（CCL5）、防御素β1（HBD1）、细胞间黏附分子-1（ICAM1）、白细胞介素-8（IL8）、肿瘤坏死因子α（TNFα）和转化生长因子-β1（TGFB1）在ATAA患者中的表达显著增加（P < 0.0001）。受试者工作特征分析表明，CCL5（0.84）、HBD1（0.83）和ICAM1（0.83）的曲线下面积值优于其他分析的蛋白质。
CCL5、HBD1和ICAM1是非常有前景的生物标志物，具有令人满意的敏感性和特异性，有助于对ATAA发生风险进行分层。这些生物标志物可能有助于诊断和随访有发生ATAA风险的患者。这项回顾性研究非常令人鼓舞；然而，进一步深入研究这些生物标志物在ATAA发病机制中的作用可能是值得的。
